This preview shows page 1. Sign up to view the full content.
Unformatted text preview: have been
correlated with the nodular melanoma subtype and with sun exposure (37-40). The
presence of NRAS mutations in tumor associated nevi and RGP lesions suggests that
NRAS activation occurs at an early stage during melanoma development (35, 36).
RAF: The RAF family of serine-threonine kinases function downstream of RAS in
signal transduction. The most commonly mutated component of RAS-RAF-ERK
pathway in melanoma is BRAF. BRAF is mutated in 50 % - 70% of melanomas and
the most common mutation is a glutamic acid for valine substitution at position 600 14 (V600E) (36, 41). About 80% of benign nevi carry this mutation as well, but so far no
mutations have been detected in uveal melanomas (42). The BRAF gene resides at
chromosome 7q34, a chromosomal region that is frequently amplified in melanoma
PI3K: Mutations of PIK3CA (encoding the p110 alpha catalytic subunit of PI3K) are
rarely detected in melanoma, and are found in less than 1% of primary melanomas
and 3% of melanoma metastases, with no evidence of amplification of any PI3K
subunit in primary melanomas by array CGH (44, 45).
AKT: Constitutive activation of AKT has been shown to be a potent oncogenic lesion
for melanocyte transformation (46). AKT3 is the major isoform deregulated in
melanoma. DNA copy gains involving the AKT3 locus have been described in
melanoma, and selective AKT3 activation may characterize 40%–60% of sporadic
tumors (47). Recent data have suggested that activation of different AKT isotypes
may result in distinct effects on cell proliferation and survival. For example, among
the three AKT isotypes, AKT3 was correlated most strongly with melanoma tumor
progression, and targeted AKT3 depletion triggered apoptotic signaling (47).
PTEN: PTEN is another important element in signal transduction altered in human
melanomas. PTEN was identified as a tumor suppressor candidate from the
chromosome region 10q23-24 which is frequently deleted in gliomas and melanomas
(48, 49). Cytogenetic evidence show...
View Full Document